The EVOLUTION HF study aimed to report real-world characteristics and treatment patterns in patients who received dapagliflozin following hospitalized heart failure, an area with minimal clinical data. In this touchCARDIO interview, we speak with Dr Gianluigi Savarese (Karolinska University Hospital, Stockholm, Sweden) to discuss the limitations of current guideline-directed medical therapies in patients with heart failure (HF) with reduced ejection fraction (HFrEF)aims and findings of the EVOLUTION HF study
The abstract entitled ‘Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What are the limitations of current guideline-directed medical therapies in patients with heart failure (HF) with reduced ejection fraction (HFrEF)? (0:35)
- What is known about the impact of dapagliflozin on HF outcomes in patients with HFrEF? (1:26)
- What were the aims and design of the EVOLUTION HF study? (2:56)
- What did the study teach us about dapagliflozin utilization following hospitalization for heart failure? (3:46)
- What is the key take home message of these findings? (4:53)
Disclosures: The study has been supported by AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
